Extract Numerous patients should benefit from the European Respiratory Society (ERS) and European Sleep Research Society (ESRS) position [1] that it is fine to use adaptive servo-ventilation (ASV) in patients whose left ventricular ejection fraction (LVEF) is at least 30%. The American Academy of Sleep Medicine (AASM) also recently endorsed using ASV to treat central sleep apnoea in patients with heart failure [2]. This is exactly what we recommended in 2016 [3] in response to AASM guidelines [4] to not use ASV in patients with primarily central sleep apnoea with LVEF below 45%.
European Respiratory Journal published a clinical update in Critical Care on 05 Mar 2026.
The item focuses on Beyond time to expand the use of adaptive servo-ventilation.
Review the original article for the full source wording and details.